Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have earned an average rating of “Moderate Buy” from the twelve brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $38.45.
Several equities analysts recently issued reports on RGNX shares. Barclays upped their price objective on shares of REGENXBIO from $45.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. Royal Bank of Canada raised REGENXBIO from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $20.00 to $35.00 in a research report on Friday, March 8th. SVB Leerink upgraded REGENXBIO from a “market perform” rating to an “outperform” rating and set a $37.00 target price for the company in a research note on Wednesday, March 6th. Raymond James reissued an “outperform” rating and issued a $45.00 price target on shares of REGENXBIO in a research note on Wednesday, February 21st. Finally, Leerink Partnrs raised shares of REGENXBIO from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 6th.
Get Our Latest Research Report on REGENXBIO
Insider Transactions at REGENXBIO
Hedge Funds Weigh In On REGENXBIO
Institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. acquired a new position in shares of REGENXBIO in the fourth quarter worth about $1,915,000. Raymond James & Associates boosted its stake in shares of REGENXBIO by 405.3% during the 3rd quarter. Raymond James & Associates now owns 100,620 shares of the biotechnology company’s stock valued at $1,656,000 after buying an additional 80,706 shares during the last quarter. Swiss National Bank grew its position in shares of REGENXBIO by 6.8% during the third quarter. Swiss National Bank now owns 86,000 shares of the biotechnology company’s stock worth $1,416,000 after buying an additional 5,500 shares in the last quarter. Hudson Bay Capital Management LP increased its stake in shares of REGENXBIO by 35.3% in the third quarter. Hudson Bay Capital Management LP now owns 115,000 shares of the biotechnology company’s stock worth $1,893,000 after buying an additional 30,000 shares during the last quarter. Finally, Trexquant Investment LP raised its holdings in REGENXBIO by 552.3% in the third quarter. Trexquant Investment LP now owns 85,913 shares of the biotechnology company’s stock valued at $1,414,000 after acquiring an additional 72,742 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.
REGENXBIO Stock Performance
REGENXBIO stock opened at $16.96 on Wednesday. REGENXBIO has a fifty-two week low of $11.83 and a fifty-two week high of $28.80. The stock has a fifty day moving average of $19.57 and a two-hundred day moving average of $17.87. The company has a market capitalization of $831.72 million, a price-to-earnings ratio of -2.81 and a beta of 1.38.
REGENXBIO (NASDAQ:RGNX – Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.16). REGENXBIO had a negative return on equity of 68.18% and a negative net margin of 291.99%. The company had revenue of $22.30 million for the quarter, compared to analysts’ expectations of $34.01 million. During the same quarter in the prior year, the business posted ($1.38) EPS. The company’s revenue for the quarter was down 28.8% compared to the same quarter last year. On average, analysts forecast that REGENXBIO will post -3.98 EPS for the current fiscal year.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Recommended Stories
- Five stocks we like better than REGENXBIO
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Garmin Navigates to New Highs Driven By Wearables Trend
- Dividend Payout Ratio Calculator
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.